TOPCHOICE MEDICAL CORPORATION 2026Q3: Operating revenue of 915 million yuan, up 2.93% year-on-year; investment income for the first three quarters increased about 3.3 times

Source: Topchoice Medical 2026 Third Quarter Report

Cumulative Net Profit Attributable to Shareholders of the Parent Company up 21.72% / Cumulative Net Profit Attributable to Shareholders of the Parent Company after deducting Non-recurring Gains and Losses up 8.44% / Cumulative Operating Revenue up 3.67%

DentalGoodNews｜On October 27, 2026, TOPCHOICE MEDICAL CORPORATION (hereinafter referred to as "TOPCHOICE MEDICAL") released its unaudited third-quarter 2026 report: single-quarter operating revenue of RMB 915 million, up 2.93% year-on-year; net profit attributable to shareholders of the listed company (hereinafter referred to as "Net Profit Attributable to Shareholders of the Parent Company") of RMB 212 million, up 3.21% year-on-year; net profit attributable to shareholders of the listed company after deducting Non-recurring Gains and Losses (hereinafter referred to as "Net Profit Attributable to Shareholders of the Parent Company after deducting Non-recurring Gains and Losses") of RMB 212 million, up 12.86% year-on-year.

Cumulative operating revenue for the first three quarters was RMB 2.501 billion, up 3.67% year-on-year; Net Profit Attributable to Shareholders of the Parent Company was RMB 670 million, up 21.72% year-on-year; Net Profit Attributable to Shareholders of the Parent Company after deducting Non-recurring Gains and Losses was RMB 537 million, up 8.44% year-on-year, a growth rate lower than the 21.72% growth of Net Profit Attributable to Shareholders of the Parent Company in the same period.

The Gross Margin for the first three quarters was 43.47%, compared with 42.65% after adjustment in the prior year period; Operating Profit was RMB 897 million, up 21.19% year-on-year; the four expenses of sales, management, R&D and finance totaled RMB 320 million, compared with RMB 324 million in the prior year period.

Source: Topchoice Medical 2026 Third Quarter Report

Investment income for the first three quarters was RMB 128 million, compared with RMB 29.7097 million in the prior year period, up 332.24% year-on-year; of which investment income from associates and joint ventures was RMB 128 million, compared with RMB 20.7344 million in the prior year period, up 518.93% year-on-year. The company stated in the report that the increase in investment income was mainly due to the increase in investment income from associates.

Net Cash Flow from Operating Activities was RMB 786 million, up 5.59% year-on-year, which the company said was mainly due to the increase in cash received from sales of goods and provision of services; net cash flow from investing activities was -RMB 782 million, compared with -RMB 311 million in the prior year period, which the company said was mainly due to the acquisition of the Optometry / Vision Care business in the current period; net cash flow from financing activities was -RMB 83.5439 million, compared with -RMB 477 million in the prior year period, which the company said was mainly due to the increase in cash received from borrowings in the current period.

Source: Topchoice Medical 2026 Third Quarter Report

As of September 30, 2026, monetary funds were RMB 618 million, compared with RMB 697 million at the end of the prior year; short-term borrowings were RMB 450 million, compared with RMB 100 million at the end of the prior year, up 350.04%, which the company said was mainly due to the increase in short-term borrowings in the current period.

In addition, the partnership term of Zhuji Topchoice Oral Medical Investment Fund Partnership (Limited Partnership) (hereinafter referred to as the "Oral Fund"), in which TOPCHOICE MEDICAL holds a stake, expired on October 27, 2026. The company stated that all investments of the Oral Fund had been completed since its establishment, but given significant changes in the industry operating environment and increasingly cautious market expectations, the development progress of some projects faces certain uncertainties. After consultation and unanimous agreement among all partners, it was decided not to extend the fund after expiration and to proceed with liquidation.

Source: Topchoice Medical Announcement on Consent to Liquidate the Participating Fund

Regarding liquidation progress, as the liquidator has not yet begun to perform its duties, the audit and valuation work involved in the distribution has not been completed; after completion, the company will submit the final distribution plan to the board of directors and the shareholders' meeting (if required) for deliberation, then put it to a vote at the fund partners' meeting, and the liquidator will implement the distribution. The company stated that the liquidation of the Oral Fund will not affect existing business or current-period profit or loss, and the final distribution amount and actual impact on owners' equity shall be subject to the liquidation results and liquidation report.

On September 2, 2026, the 2,833,164 shares repurchased by TOPCHOICE MEDICAL completed cancellation registration with China Securities Depository and Clearing Corporation Limited, and total share capital changed from 447,289,117 shares to 444,455,953 shares. On October 27, 2026, the 16th meeting of the 10th board of directors of TOPCHOICE MEDICAL deliberated and approved the 2026 third-quarter profit distribution plan: a cash dividend of RMB 4.5 per 10 shares (tax inclusive), which, based on the total share capital of 444,455,953 shares as of September 30, totals RMB 200 million (tax inclusive), accounting for 29.85% of the Net Profit Attributable to Shareholders of the Parent Company for the first three quarters; the plan does not involve bonus shares or capitalization of capital reserve, and is still subject to deliberation by the shareholders' meeting.